TEZSPIRE clears every major Phase 3 hurdle in EoE. Could blocking TSLP reshape another disease?
Amgen and AstraZeneca say TEZSPIRE achieved both co-primary and all key secondary endpoints in the Phase 3 CROSSING study, potentially extending the TSLP-blocking biologic into eosinophilic esophagitis.